InnoCyto Inc.
15375 Barranca Pkwy, Suite I-103
Irvine, CA 92618

Technical Data Sheet

APC Conjugated Human IL13RA2 Protein (C-Fc)

Catalog Number: 805003, 805004
Size: 25 ug, 100 ug
Target Name: IL13RA2, CD213A2, IL-13R, IL13BP
Regulatory Status: RUO

Product Details

Application: FC
Format: Liquid, APC
Expression Host: CHO
Species: Human
Sources: Recombinant Human IL13RA2 protein (Cys22-Leu342) with C-terminus Fc tag is expressed in CHO cells and conjugated to APC.
Accession Number: Q14627
Molecular Weight: The protein has a predicted molecular weight of 63.5 kDa. Under DTT-reducing conditions, it migrates at approximately 65-80 kDa on SDS-PAGE prior to conjugation.
Affinity Tag: C-Fc
Formulation: 1xPBS buffer, pH7.4, 0.09% NaN3 with a carrier protein
Endotoxin level: Not tested
Protein Concentration: 25μg size is bottled at 0.1mg/mL concentration. 100 μg size is bottled at lot specific concentration.
Storage and Handling: Briefly centrifuge the vial upon receipt. An unopened vial may be stored at 2–8°C for up to six months.

Background Information

CD213A2, also known as IL13R?2, is a type I transmembrane protein belonging to the hematopoietin receptor family. It binds interleukin-13 (IL-13) with high affinity but lacks a functional cytoplasmic signaling domain, suggesting that it primarily acts as a decoy receptor, antagonizing IL-13 signaling mediated by the IL-13R?1/IL-4R? complex. IL13R?2 is expressed in fibroblasts, smooth muscle cells, keratinocytes, and activated B cells, though its surface expression is tightly regulated and much of it resides intracellularly or in soluble form. In addition to inhibiting IL-13 activity, IL13R?2 has been reported to suppress IL-4 signaling via physical interaction with IL-4R?, while paradoxically promoting TGF-? production and fibrosis. Importantly, IL13R?2 is highly and specifically overexpressed in certain cancers, such as glioblastoma multiforme and high-grade astrocytomas, making it a promising target for tumor-specific immunotherapies and viral vector-mediated gene delivery approaches.